New Stock News | Tse Ling Biochemistry Files with Hong Kong Stock Exchange
On January 13, Chengdu Zeran Biotechnology Co., Ltd. (referred to as Zeran Biotechnology) submitted an application for listing to the main board of the Hong Kong Stock Exchange, with Jefferies and CICC serving as joint sponsors.
On January 13, Chengdu Zelin Biopharmaceutical Technology Co., Ltd. (referred to as Zelin Biopharma) submitted an application to list on the main board of the Hong Kong Stock Exchange, with Jefferies and CICC as its joint sponsors. According to the prospectus, Zelin Biopharma is a late-stage biotechnology company dedicated to integrating structural biology, artificial intelligence, and clinical disease models to develop highly differentiated small molecule therapies with unique potential for breakthrough or best-in-class.
Related Articles
CABBEEN (02030) will distribute a final dividend of HK$0.0092 per share on May 8th.
CATHAY PAC AIR (00293) will distribute its second interim dividend of 0.64 Hong Kong dollars per share on May 7th.
FE HORIZON (03360) released its 2025 annual performance, with a net profit attributable to shareholders of 3.889 billion yuan, a year-on-year increase of 0.67%.
CABBEEN (02030) will distribute a final dividend of HK$0.0092 per share on May 8th.
CATHAY PAC AIR (00293) will distribute its second interim dividend of 0.64 Hong Kong dollars per share on May 7th.
FE HORIZON (03360) released its 2025 annual performance, with a net profit attributable to shareholders of 3.889 billion yuan, a year-on-year increase of 0.67%.
RECOMMEND
Local Policies Experiment With “Lobster” AI Agents Accelerate Into The Agent Era But Security Risks Remain
10/03/2026
Hong Kong And Macau Join Billion‑Level Guidance Fund Initiative Hong Kong Sets Return‑Investment KPI Macau Targets MOP 20 Billion
10/03/2026
Southbound Capital Sells Heavily Yet Hang Seng Tech Advances How Do Fund Managers Interpret It
10/03/2026
